title: PPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance.
abstract: Hypertriglyceridemia is an important risk factor associated with insulin resistance and β-cell dysfunction. This study investigated the effects of hypertriglyceridemia and fenofibrate treatment on insulin sensitivity and β-cell function in subjects with normal glucose tolerance. A total of 1974 subjects with normal glucose tolerance were divided into the normal TG group (NTG group, n = 1302) and hypertriglyceridemia group (HTG group, n = 672). Next, 92 patients selected randomly from 672 patients with hypertriglyceridemia were assigned to a 24-week fenofibrate treatment. The HTG group had increased waist circumference (WC), body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR), and homeostasis model assessment of β-cell function (HOMA-β) and decreased high-density lipoprotein cholesterol (HDL-C) compared with the NTG group (all P < 0.01). The 24-week fenofibrate treatment significantly decreased the WC, BMI, TG, HOMA-IR, and HOMA-β levels and increased the HDL-C levels in the patients with hypertriglyceridemia (WC, BMI, and HOMA-IR: P < 0.05; TG, HDL-C, and HOMA-β: P < 0.01). The fenofibrate treatment significantly alleviated insulin resistance and reduced the secreting load of β-cells in the hypertriglyceridemia patients with normal glucose tolerance.
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Cardiology, Beijing No. 6 Hospital, Beijing 100007, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Lu
authors.affiliation: Physical Examination Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Yanjin
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Yumei
authors.initials: Y
authors.lastname: Jia
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Yang
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Fu
authors.affiliation: Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Guang
authors.identifier: 0000-0002-3810-1419
authors.initials: G
authors.lastname: Wang